全文获取类型
收费全文 | 1317篇 |
免费 | 67篇 |
国内免费 | 58篇 |
专业分类
1442篇 |
出版年
2024年 | 7篇 |
2023年 | 28篇 |
2022年 | 36篇 |
2021年 | 63篇 |
2020年 | 54篇 |
2019年 | 66篇 |
2018年 | 60篇 |
2017年 | 35篇 |
2016年 | 49篇 |
2015年 | 44篇 |
2014年 | 73篇 |
2013年 | 118篇 |
2012年 | 42篇 |
2011年 | 59篇 |
2010年 | 41篇 |
2009年 | 53篇 |
2008年 | 55篇 |
2007年 | 60篇 |
2006年 | 53篇 |
2005年 | 46篇 |
2004年 | 55篇 |
2003年 | 34篇 |
2002年 | 36篇 |
2001年 | 17篇 |
2000年 | 22篇 |
1999年 | 24篇 |
1998年 | 15篇 |
1997年 | 25篇 |
1996年 | 12篇 |
1995年 | 19篇 |
1994年 | 10篇 |
1993年 | 17篇 |
1992年 | 19篇 |
1991年 | 9篇 |
1990年 | 5篇 |
1989年 | 14篇 |
1988年 | 3篇 |
1987年 | 4篇 |
1986年 | 15篇 |
1985年 | 7篇 |
1984年 | 11篇 |
1983年 | 4篇 |
1982年 | 4篇 |
1981年 | 5篇 |
1980年 | 4篇 |
1979年 | 2篇 |
1977年 | 1篇 |
1976年 | 3篇 |
1974年 | 2篇 |
1972年 | 1篇 |
排序方式: 共有1442条查询结果,搜索用时 15 毫秒
31.
32.
禽流感是由正黏液病毒科甲型流感病毒引起的对人类健康和社会发展构成极大威胁的烈性传染病,高致病性禽流感暴发突然,具有极高的发病率和死亡率。目前具有确切疗效的抗禽流感治疗药物品种很少,公认的药物只有奥塞米韦,此外流感病毒的抗药性也是一个重要的问题,近年来出现的甲型H1N1病毒更给人类敲响了警钟,因此研究更多的治疗药物和治疗手段对于禽流感的防控十分必要。从禽流感治疗化学药物和生物药物几个方面对禽流感治疗研究进展进行了综述。 相似文献
33.
分析2015年至2019年辽宁省人民医院血培养分离菌的科室分布及耐药情况,为临床提供数据参考.利用Whonet5.6软件对2015年至2019年辽宁省人民医院血培养临床数据进行分析.血培养阳性率为12.3%,共分离病原菌1266株,其中革兰阴性菌546株、革兰阳性菌649株、真菌71株;革兰阴性菌主要为大肠埃希菌(Es... 相似文献
34.
《Revista espa?ola de geriatría y gerontología》2016,51(4):217-220
BackgroundThe use of anticholinergic drugs in the elderly has been associated to an increased frequency of delirium. There are different scales for estimating the anticholinergic burden, such as the Anticholinergic Drug Scale (ADS), Anticholinergic Risk Scale (ARS), and Anticholinergic Cognitive Burden (ACB). The aim of the study is to establish the relationship between anticholinergic burden measured by ADS, ARS, and ACB scales and incident or prevalent delirium.MethodsAn ambispective observational study was conducted for 76 days in the acute geriatric unit of a tertiary hospital. All patients over 80 years-old were included, except re-admissions or those subjected to palliative care. The data collected included sex, age, chronic medication and any recent changes, recent drugs prescribed prior to an episode of delirium, chronic kidney disease, diabetes mellitus, dementia, visual and auditory impairment, and their combination as sensory impairment, previous falls, stroke, brain tumour, and incident and prevalent delirium.ResultsA total of 72 patients were included. Incident delirium was detected in 8.1% of the patients, and prevalent delirium in 40.9%. A statistically significant association was established between anticholinergic drugs and the incident delirium measured by the ARS scale (P=.017). None of the scales was able to establish a significant association with prevalent delirium.ConclusionThe ARS scale was related to new episodes of delirium. All scales were insufficient when it came to establishing an association with prevalent delirium. 相似文献
35.
36.
《Bioorganic & medicinal chemistry》2016,24(15):3291-3303
The characterization of the target proteins of drug molecules has become an important goal in understanding its mode of action and origin of side effects due to off-target binding. This is especially important for covalently binding drugs usually containing electrophilic moieties, which potentially can react with nucleophilic residues found in many proteins. This review gives a comprehensive overview of the use of activity-based protein profiling (ABPP) as an efficient tool for the target identification of covalently binding drugs. 相似文献
37.
《Bioorganic & medicinal chemistry》2016,24(7):1419-1430
Parkinson’s disease (PD) is a common chronic degenerative disease of the central nervous system. Due to a rapidly aging society worldwide, PD morbidity is on the rise; however, the treatment of PD with conventional drugs carries serious adverse reactions and cannot fix the root cause of PD, the degeneration of dopaminergic neurons, which limits conventional drug usage in clinical practice. In recent years, research on the pathogenesis of PD and its clinical manifestations has led to the discovery of an increasing number of novel targets in PD, including several small molecule targeted compounds. In this paper, we analyze and summarize the most recently published PD literature and review several recently discovered novel targets in PD and their small molecule targeted pharmacologically active agents based on their mechanisms of action and pharmacodynamic profiles. 相似文献
38.
通过对治疗前后腹泻羔羊粪便细菌检查及临床观察,以查明两种抗菌药物对腹泻羔羊肠道细菌的影响。结果表明,腹泻羔羊治疗前粪便中的革兰氏阳性杆菌,革兰氏阳性球菌及革兰氏阴性杆菌的比例分别为20%、10%和70%。用敌菌净治疗的效果显著,其羔羊肠道细菌的比例接近健康羔羊。用庆大霉素治疗的羔羊,部分出现不良反应,其肠道细菌出现失调状态。 相似文献
39.
Cook JC Jacobson CF Gao F Tassinari MS Hurtt ME DeSesso JM 《Birth defects research. Part B, Developmental and reproductive toxicology》2003,68(1):5-26
BACKGROUND: Nonsteroidal anti‐inflammatory drugs (NSAIDs) are among the most commonly prescribed to pregnant women. Some case‐control studies have linked the NSAIDs aspirin and indomethacin with a risk of congenital abnormalities and low birthweight. High doses of aspirin produce developmental toxicity in rats (e.g., gastroschisis/umbilical hernia, diaphragmatic hernia [DH]) when administered during sensitive windows of development. Unlike other NSAIDs, aspirin irreversibly inhibits cyclooxygenases (COXs) 1 and 2. Hence, the developmental toxicity seen in rats after exposure to aspirin may be due to the irreversible inhibition of COX‐1 and/or COX‐2. If so, other NSAIDs, which act through a reversible inhibition of COX, may produce a weak developmental toxicity signal or no developmental toxicity signal when tested in preclinical models. To investigate this relationship, a comprehensive analysis of the NSAID developmental toxicity literature was undertaken to determine whether NSAIDs other than aspirin induce developmental anomalies similar to those elicited by aspirin. METHODS: Developmental toxicity studies were identified through literature searches of PubMed and TOXNET, and pregnancy outcome data were extracted and tabulated. By using a set of defined criteria, each study was evaluated for quality and assigned to one of five tiers. The relation between certain malformations and NSAID treatment was analyzed for the best studies (tiers 1–4) by using concurrent control data (Mantel–Haenszel and permutation tests) and by combining the concurrent control data with historical control data (χ2 test and permutation tests). RESULTS: A qualitative analysis of these data led to a focus on three types of malformations: DH, ventricular septal defects (VSDs), and midline defects (MDs). In rats, the incidences of VSD and MD were increased among fetuses treated with NSAIDs when compared with the concurrent controls. The extent of the increase was attenuated when the data from the aspirin studies were excluded from the analysis. There were no qualifying (i.e., tiers 1–4) aspirin studies conducted in rabbits, but the incidences of the three defects were increased over control incidences among non‐aspirin NSAID‐treated animals. Statistical analysis of these data was subsequently conducted. When tiers 1–4 were combined and compared with concurrent controls plus the most appropriate historical control database, the strongest associations were between NSAID treatment and VSD in rats, VSD in rabbits, and MD in rabbits. There also was some suggestion of an association between NSAID treatment and DH in rabbits. CONCLUSIONS: This analysis of the non‐clinical NSAID literature demonstrated a possible association between exposure to NSAIDs and developmental anomalies. The anomalies were similar for aspirin and for other NSAIDs, but effects occurred at a much lower incidence with non‐aspirin NSAIDs than previously reported with aspirin. Such a finding is consistent with the concept that reversible inhibition of COX‐1 and/or COX‐2 by other NSAIDs would produce weaker developmental toxicity signals than aspirin. However, there were limitations of the evaluated studies: (1) there were very few robust International Conference on Harmonization–compliant studies conducted with NSAIDs in the published literature; (2) many of the studies were conducted at doses well below the maximum tolerated dose (MTD), where effects are rarely seen; and (3) numerous studies were conducted above the MTD, where reduced numbers of fetuses hampered detection of low‐incidence findings. Although weak associations were observed, these limitations prevented us from definitively determining the presence or absence of a developmental toxicity signal from the existing body of NSAID data. Further exploration of this hypothesis will require assessing the potential association in animal models by using dose levels centered around the MTD. Birth Defects Research (Part B) 68:5–26, 2003. © 2003 Wiley‐Liss, Inc. 相似文献
40.
目的:探讨无创血流动力学监测技术在严重脓毒症患者液体复苏后指导血管活性药物使用的意义。方法:选择2014年6月至2016年6月我院急诊处收治的严重脓毒症患者56例为研究对象,分为观察组和对照组,每组各28例。对照组进行常规对症治疗,观察组在对照组治疗基础上使用无创血流动力学监测仪指导治疗。观察两组患者在治疗前及治疗后6 h血流动力学及微循环灌注指标、液体复苏6 h后液体平衡量及血管活性药物使用量,及在重症监护病房(EICU)的入住时间。结果:治疗后两组患者尿量均大于30 m L/h,提示复苏成功。两组患者治疗后血液动力学指标和微循环灌注指标较治疗前均明显好转(均P0.05);治疗后,两组间血液动力学指标和微循环灌注指标比较无明显差异(P0.05)。观察组液体复苏6 h后液体平衡量明显少于对照组(P0.05),观察组血管活性药物用量均明显高于对照组(P0.05),观察组患者在EICU病房住院时间明显短于对照组(P0.05)。结论:无创血流动力学监测对严重脓毒症患者的液体恢复管理和治疗过程具有指导意义,使血管活性药物得到有效利用,精确进行液体管理,减少盲目补液,缩短病程,减少患者的住院时间,经济高效,是指导治疗和评估治疗疗效的重要手段。 相似文献